company background image
1JS logo

Shield Therapeutics DB:1JS Stock Report

Last Price

€0.029

Market Cap

€25.7m

7D

0%

1Y

-58.0%

Updated

23 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Shield Therapeutics plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shield Therapeutics
Historical stock prices
Current Share PriceUK£0.029
52 Week HighUK£0.09
52 Week LowUK£0.0095
Beta1.53
1 Month Change-14.71%
3 Month Change-28.40%
1 Year Change-57.97%
3 Year Change-92.60%
5 Year Change-98.67%
Change since IPO-98.58%

Recent News & Updates

Recent updates

Shareholder Returns

1JSDE PharmaceuticalsDE Market
7D0%-2.2%-2.0%
1Y-58.0%-15.6%6.9%

Return vs Industry: 1JS underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.

Return vs Market: 1JS underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is 1JS's price volatile compared to industry and market?
1JS volatility
1JS Average Weekly Movement16.3%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 1JS's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 1JS's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
200873Anders Lundstromwww.shieldtherapeutics.com

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Shield Therapeutics plc Fundamentals Summary

How do Shield Therapeutics's earnings and revenue compare to its market cap?
1JS fundamental statistics
Market cap€25.68m
Earnings (TTM)-€34.66m
Revenue (TTM)€20.58m

1.2x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1JS income statement (TTM)
RevenueUS$21.47m
Cost of RevenueUS$13.65m
Gross ProfitUS$7.83m
Other ExpensesUS$43.99m
Earnings-US$36.17m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.046
Gross Margin36.44%
Net Profit Margin-168.42%
Debt/Equity Ratio3,637.5%

How did 1JS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:15
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shield Therapeutics plc is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Howard MillerCanaccord Genuity
Stuart HarrisCavendish
Alexander PyeCavendish